Skip to main content

Table 5 AEs during 180-day follow-up

From: Effects of omeprazole or pantoprazole on platelet function in non-ST-segment elevation acute coronary syndrome patients receiving clopidogrel

Characteristic Omeprazole group (n = 303) Pantoprazole group (n = 304) P value
Stent thrombosis [n (%)] 0 0
MACEs [n (%)] 8 (2.6) 7 (2.3) 0.80
 Cardiac death 1 (0.3) 0 0.50
 Myocardial infarction 0 0
 Ischemic symptoms driven target vessel revascularization 3 (1.0) 1 (0.3) 0.37
 Non-target vessel revascularization 6 (2.0) 6 (2.0) 1.00
Recurrent angina [n (%)] 30 (9.9) 24 (7.9) 0.40
All-cause death [n (%)] 1 (0.3)a 1 (0.3)b 1.00
TIMI bleeding evens [n (%)] 15 (5.0) 19 (6.3) 0.60
 Major 0 1 (0.3) 1.00
 Moderate 0 3 (1.0) 0.25
 Minor 16 (5.3) 14 (4.6) 0.71
Stroke [n (%)] 1 (0.3) 0 0.50
Adverse drug reactions [n (%)] 17 (5.6) 19 (6.3) 0.86
AEs [n (%)] 50 (16.5) 44 (14.5) 0.50
  1. aOne patient died due to lung cancer in the omeprazole group
  2. bOne patient died due to acute brainstem hemorrhage in the pantoprazole group